Moore Donald C, Eagers Keren A, Janes Amanda, Pineda-Roman Mauricio
Levine Cancer Institute, Atrium Health, Concord, NC, USA.
Department of Pharmacy, Atrium Health, Concord, NC, USA.
J Oncol Pharm Pract. 2023 Jan;29(1):239-241. doi: 10.1177/10781552221102318. Epub 2022 May 18.
Tafasitamab is an anti-CD19 monoclonal antibody indicated for the treatment of relapsed/refractory diffuse large B-cell lymphoma to be given in combination with lenalidomide. Experiences with tafasitamab in the setting of hemodialysis are limited and the efficacy and safety of this agent in this setting are unknown.
We describe a patient with relapsed/refractory diffuse large B-cell lymphoma with hemodialysis-dependent end-stage renal disease who successfully received tafasitamab/lenalidomide.
Tafasitamab and reduced dose lenalidomide were initiated for relapsed diffuse large B-cell lymphoma. Tafasitamab was administered on non-dialysis days. Follow-up imaging for disease response assessment demonstrated a complete response. Therapy was well tolerated; the only major toxicity experienced was grade 4 neutropenia that resolved with dose adjustment to lenalidomide. Over a year from initiating therapy, the patient remains in a complete response.
DISCUSSION/CONCLUSION: The combination of tafasitamab and dose-reduced lenalidomide produced a complete response in the treatment of relapsed/refractory diffuse large B-cell lymphoma in the setting of chronic intermittent hemodialysis.
塔法西他单抗是一种抗CD19单克隆抗体，适用于与来那度胺联合治疗复发/难治性弥漫性大B细胞淋巴瘤。在血液透析环境中使用塔法西他单抗的经验有限，该药物在此环境中的疗效和安全性尚不清楚。
我们描述了一名患有复发/难治性弥漫性大B细胞淋巴瘤且依赖血液透析的终末期肾病患者，该患者成功接受了塔法西他单抗/来那度胺治疗。
开始使用塔法西他单抗和减量的来那度胺治疗复发的弥漫性大B细胞淋巴瘤。塔法西他单抗在非透析日给药。用于疾病反应评估的随访影像学检查显示完全缓解。治疗耐受性良好；唯一经历的主要毒性是4级中性粒细胞减少症，通过调整来那度胺剂量得以缓解。自开始治疗一年多来，患者仍处于完全缓解状态。
讨论/结论：在慢性间歇性血液透析的情况下，塔法西他单抗和减量的来那度胺联合用药在治疗复发/难治性弥漫性大B细胞淋巴瘤中产生了完全缓解。
